The virus can hide silently for up to three weeks
Since mid-May 2026, a resurgence of Ebola — this time carried by the Bundibugyo strain — has crossed from the Democratic Republic of Congo into Uganda, drawing the World Health Organization into a declared international emergency. With over 900 suspected cases and 176 suspected deaths in less than two weeks, the outbreak confronts humanity with a familiar and humbling truth: that a virus requiring only touch to travel can outpace even our most vigilant systems of response. What makes this moment especially sobering is not the ferocity of the pathogen, but the emptiness of our medical cabinet against it — no approved vaccine, no targeted treatment, only the ancient tools of isolation and contact tracing standing between containment and catastrophe.
- The Bundibugyo strain of Ebola emerged in Congo on May 15th and within days had appeared independently in Uganda's capital, signaling the virus was already circulating unseen through communities.
- With a silent incubation window of up to three weeks, infected individuals move freely — visiting family, entering clinics — before any symptom betrays their condition, making containment a race against invisibility.
- Unlike the Zaire strain that devastated West Africa a decade ago, Bundibugyo has no approved vaccine and no specific treatment, leaving medical teams with only supportive care and the hope that immune systems hold.
- The WHO declared a public health emergency of international concern on May 17th, but with 176 suspected deaths already recorded and case counts still climbing, the outbreak's trajectory remains deeply alarming.
- Health authorities are falling back on the oldest defenses — rapid case detection, isolation, contact tracing, and community behavior change — in regions where fragile infrastructure and limited institutional trust make each of those steps harder than it sounds.
On May 15th, health officials in the Democratic Republic of Congo confirmed the first Ebola case caused by the Bundibugyo strain. Within two days, two unconnected cases appeared in Kampala, Uganda — a detail that suggested the virus was already moving silently through the population. By late May, the WHO was tracking more than 900 suspected cases across both countries, with 101 confirmed infections and 176 suspected deaths. The speed of spread prompted the WHO to declare an international public health emergency on May 17th.
What distinguishes this outbreak is not how the virus travels, but what medicine cannot do to stop it. Ebola spreads only through direct contact with the bodily fluids of an infected person — it does not move through the air. Yet its incubation period of two to twenty-one days creates a dangerous window in which infected people, unaware they are sick, continue living normally among family and community. By the time symptoms appear, chains of transmission may already be long.
The Bundibugyo strain has circulated in Central Africa before, but it is not the strain the world's medical arsenal was built to fight. The Zaire strain — responsible for the catastrophic 2014–2016 West African epidemic — now has approved vaccines and treatments. Bundibugyo has neither. Doctors can only manage symptoms and hope the patient's immune system prevails. The disease progresses from sudden high fever and severe muscle pain into, in the worst cases, a hemorrhagic collapse: plummeting platelet counts, organ failure, and internal bleeding.
With no vaccine, no targeted treatment, and no rapid diagnostic test specific to this strain, the entire response rests on the oldest tools of public health — finding cases fast, isolating the sick, tracing contacts, and changing behavior. In a region where healthcare infrastructure is fragile and community trust in authorities is limited, those tools alone face a formidable test. The virus, for now, is moving faster than the response meant to stop it.
On May 15th, health officials in the Democratic Republic of Congo confirmed the first case of Ebola caused by the Bundibugyo strain. Within two days, two more cases appeared in Kampala, Uganda—unconnected to each other, suggesting the virus was already moving through the population. By late May, the World Health Organization was tracking more than 900 suspected cases across both countries, with 101 confirmed infections and 176 suspected deaths recorded as of May 22nd. The speed of spread was alarming enough that on May 17th, the WHO declared the outbreak a public health emergency of international concern.
What makes this outbreak particularly dangerous is not how the virus travels, but what we cannot do to stop it. Ebola spreads only through direct contact with the bodily fluids of an infected person—blood, secretions, feces, vomit—or through contact with animals that have died from the disease. It does not travel through the air like measles or COVID-19. A person must have significant, direct exposure to become infected. Yet this very specificity creates a false sense of control. The virus has an incubation period of two to twenty-one days, with most people showing symptoms between five and ten days after exposure. During that window, an infected person may not know they are sick, moving freely through communities, touching family members, visiting clinics where healthcare workers have no reason to suspect Ebola.
The Bundibugyo strain is a variant of Ebola that has circulated in Central Africa before, but it is not the strain most of the world's medical arsenal was built to fight. The Zaire strain, which caused the devastating West African epidemic of 2014-2016, now has approved vaccines and therapeutic treatments. Bundibugyo has neither. There is no vaccine to prevent infection. There is no specific drug to treat it once someone falls ill. Doctors can only manage symptoms—fluids, blood transfusions, organ support—and hope the patient's immune system prevails.
The disease itself progresses in stages that mirror the worst presentations of dengue fever. It begins with sudden, high fever accompanied by severe muscle pain and gastrointestinal symptoms. In severe cases, it advances to hemorrhagic signs: platelet counts plummet, blood pressure crashes, organs fail, and bleeding erupts from the mouth and digestive tract. The mortality rate varies by strain and setting, but Bundibugyo has proven lethal in past outbreaks. With 176 suspected deaths already reported and cases still climbing, the mathematics of the outbreak are grim.
The absence of medical tools—vaccine, treatment, or even a rapid diagnostic test specific to this strain—means the response must rely entirely on the oldest public health measures: finding cases quickly, isolating the sick, tracing contacts, and breaking chains of transmission through behavior change and infection control. In a region where healthcare infrastructure is fragile, where communities have limited trust in authorities, and where the virus can hide silently for up to three weeks, these measures alone may not be enough. The race is between the speed of detection and the speed of spread, and so far, the virus is winning.
Citas Notables
The WHO emphasized that unlike the Zaire strain, which has approved vaccines and treatments, there is no therapeutic or immunization specific to the Bundibugyo virus— World Health Organization
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this is the Bundibugyo strain and not Zaire?
Because we have weapons for Zaire—vaccines, drugs—and we have none for Bundibugyo. It's the difference between a fire we know how to fight and one we're learning about in real time.
But you said it doesn't spread through the air. Doesn't that make it easier to control?
In theory, yes. In practice, it means we have to find every case and trace every contact, which is much harder than it sounds when people are sick for weeks before they know it.
What happens to someone who gets it?
It starts like flu—fever, muscle pain. Then in severe cases, the body begins to fail. Bleeding, organ shutdown. It's brutal and fast.
How many people are actually sick right now?
One hundred and one confirmed. But they're tracking over 900 suspected cases. The gap between those numbers tells you how overwhelmed the system is.
What's the incubation period again?
Two to twenty-one days, usually five to ten. That's the danger window—someone is contagious but doesn't know they're sick yet.
So what happens next?
They either find a way to vaccinate people quickly, or they rely on isolation and contact tracing. Without the vaccine, it's going to be a long fight.